AU2007305443B2 - Compositions and methods for diagnosing and treating cancer - Google Patents

Compositions and methods for diagnosing and treating cancer Download PDF

Info

Publication number
AU2007305443B2
AU2007305443B2 AU2007305443A AU2007305443A AU2007305443B2 AU 2007305443 B2 AU2007305443 B2 AU 2007305443B2 AU 2007305443 A AU2007305443 A AU 2007305443A AU 2007305443 A AU2007305443 A AU 2007305443A AU 2007305443 B2 AU2007305443 B2 AU 2007305443B2
Authority
AU
Australia
Prior art keywords
antibody
seq
antibodies
dll4
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007305443A
Other languages
English (en)
Other versions
AU2007305443A1 (en
Inventor
Fumiko Axelrod
Austin Gurney
Timothy Hoey
Sanjeev Satyal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomed Pharmaceuticals Inc
Original Assignee
Oncomed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals Inc filed Critical Oncomed Pharmaceuticals Inc
Publication of AU2007305443A1 publication Critical patent/AU2007305443A1/en
Application granted granted Critical
Publication of AU2007305443B2 publication Critical patent/AU2007305443B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2007305443A 2006-09-29 2007-09-28 Compositions and methods for diagnosing and treating cancer Active AU2007305443B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US84790406P 2006-09-29 2006-09-29
US60/847,904 2006-09-29
US88626007P 2007-01-23 2007-01-23
US60/886,260 2007-01-23
US94254207P 2007-06-07 2007-06-07
US60/942,542 2007-06-07
PCT/US2007/020889 WO2008042236A2 (en) 2006-09-29 2007-09-28 Compositions and methods for diagnosing and treating cancer

Publications (2)

Publication Number Publication Date
AU2007305443A1 AU2007305443A1 (en) 2008-04-10
AU2007305443B2 true AU2007305443B2 (en) 2012-08-23

Family

ID=39268983

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007305443A Active AU2007305443B2 (en) 2006-09-29 2007-09-28 Compositions and methods for diagnosing and treating cancer

Country Status (27)

Country Link
US (5) US7750124B2 (OSRAM)
EP (3) EP2066694B1 (OSRAM)
JP (3) JP5535633B2 (OSRAM)
KR (1) KR101477824B1 (OSRAM)
AU (1) AU2007305443B2 (OSRAM)
BR (1) BRPI0717431A2 (OSRAM)
CA (1) CA2664738C (OSRAM)
CO (1) CO6180466A2 (OSRAM)
CR (1) CR10667A (OSRAM)
CY (1) CY1117154T1 (OSRAM)
DK (1) DK2066694T3 (OSRAM)
EA (1) EA018260B1 (OSRAM)
ES (1) ES2557953T3 (OSRAM)
HR (1) HRP20160082T1 (OSRAM)
HU (1) HUE028379T2 (OSRAM)
IL (1) IL197721A (OSRAM)
MA (1) MA30808B1 (OSRAM)
ME (1) ME02371B (OSRAM)
MX (1) MX2009003229A (OSRAM)
NO (1) NO20091635L (OSRAM)
NZ (1) NZ576404A (OSRAM)
PL (1) PL2066694T3 (OSRAM)
PT (1) PT2066694E (OSRAM)
RS (1) RS54452B1 (OSRAM)
SI (1) SI2066694T1 (OSRAM)
WO (1) WO2008042236A2 (OSRAM)
ZA (1) ZA200901615B (OSRAM)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
EP3424529A1 (en) 2007-07-02 2019-01-09 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US8119366B2 (en) * 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US8034337B2 (en) * 2008-05-30 2011-10-11 Xbiotech, Inc. Interleukin-1α antibodies
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
CN102316897B (zh) * 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
AU2009294415B2 (en) * 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
MX2011000455A (es) 2008-11-07 2011-02-25 Galaxy Biotech Llc Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
EP2470568A2 (en) * 2009-08-29 2012-07-04 Abbott Laboratories Therapeutic dll4 binding proteins
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
PL2488204T3 (pl) * 2009-10-16 2016-10-31 Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
WO2011068840A1 (en) * 2009-12-01 2011-06-09 Oncomed Pharmaceuticals, Inc. Methods for treating cancers comprising k-ras mutations
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011205316B2 (en) 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
EP3072904A1 (en) 2010-03-02 2016-09-28 Abbvie Inc. Therapeutic dll4 binding proteins
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
SG188190A1 (en) 2010-08-03 2013-04-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2606353A4 (en) * 2010-08-18 2014-10-15 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASE
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US20130323265A1 (en) * 2010-11-15 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
KR101621036B1 (ko) 2011-03-27 2016-05-13 온코스템 다이아그노틱스 (모리셔스) 프라이빗 리미티드 종양 세포를 동정하기 위한 마커, 그의 방법 및 키트
US8685401B2 (en) * 2011-06-17 2014-04-01 Adrian Harris Methods of enhancing the response to radiation in tumor therapy using anti-DLL4 antibodies
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
WO2013039954A1 (en) * 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
DK3485903T5 (da) * 2011-09-23 2024-09-02 Mereo Biopharma 5 Inc Vegf/dll4-bindende midler og anvendelser deraf
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2014062245A2 (en) 2012-05-31 2014-04-24 Sorrento Therapeutics Inc. Antigen binding proteins that bind dll-4
EP2858673A4 (en) 2012-06-06 2016-06-22 Oncomed Pharm Inc BINDING AGENTS MODULATING THE HIPPO SIGNALING PATH AND USES THEREOF
KR20150036603A (ko) 2012-07-13 2015-04-07 온코메드 파마슈티칼스, 인크. Rspo3 결합제 및 그의 용도
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
WO2014062659A2 (en) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Methods of treating ocular diseases
AU2013337811A1 (en) * 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
AR093788A1 (es) 2012-12-04 2015-06-24 Oncomed Pharm Inc Inmunoterapia con agentes de enlace
JP6449537B2 (ja) * 2012-12-27 2019-01-09 日本メジフィジックス株式会社 抗腫瘍剤、及び、抗腫瘍用キット
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
GB201312727D0 (en) * 2013-07-16 2013-08-28 Isis Innovation Modulators
RS58719B1 (sr) 2013-08-01 2019-06-28 Five Prime Therapeutics Inc Nefukozilisana anti-fgfr2iiib antitela
CN105829547A (zh) 2013-12-02 2016-08-03 昂科梅德制药有限公司 与Wnt途径抑制剂有关的预测性生物标记物的鉴别
JPWO2015108203A1 (ja) 2014-01-15 2017-03-23 株式会社オーダーメードメディカルリサーチ 抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物
DK3172227T3 (da) * 2014-07-21 2019-12-02 Delinia Inc Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
TW201628648A (zh) 2014-09-16 2016-08-16 安可美德藥物股份有限公司 纖維變性疾病之治療
JP6827415B2 (ja) 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
ES2968074T3 (es) * 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
CN108368174B (zh) 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2017201504A1 (en) 2016-05-19 2017-11-23 Santa Anna Tech Llc Ablation catheter with integrated cooling
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
EP3504245A4 (en) * 2016-08-23 2020-04-22 The Regents of The University of California PROTEOLYTICLY CLEAVABLE CHIMERAL POLYPEPTIDES AND METHOD FOR USE THEREOF
JP7224289B2 (ja) 2016-09-21 2023-02-17 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ１２３結合タンパク質並びに関連する組成物及び方法
EA201991142A1 (ru) 2016-11-08 2019-10-31 Варианты il-2 для лечения аутоиммунных заболеваний
NZ753515A (en) 2016-11-30 2022-02-25 Oncomed Pharm Inc Methods for treatment of cancer comprising tigit-binding agents
US11091555B2 (en) 2017-05-16 2021-08-17 Five Prime Therapeutics, Inc. Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
EP3801324B1 (en) 2018-06-01 2025-05-28 Aqua Medical, Inc. Vapor generation and delivery systems
JP2022511318A (ja) 2018-09-11 2022-01-31 アクア、ハート、インコーポレイテッド 心臓疾患を処置するための加熱蒸気焼灼システムおよび方法
EP3880697A2 (en) 2018-11-15 2021-09-22 OncoMed Pharmaceuticals, Inc. Methods and monitoring of treatment with vegf/dll4 binding agent
WO2021041818A1 (en) 2019-08-28 2021-03-04 Santa Anna Tech Llc Systems and methods for ablating prostate tissue
CN115666426B (zh) 2020-01-15 2025-11-21 水医疗股份有限公司 具有对蒸汽输送的简化控制的蒸汽消融系统
WO2022077020A1 (en) 2020-10-08 2022-04-14 Santa Anna Tech Llc Visualization-enabled ablation catheters, systems, and methods
WO2023149977A1 (en) * 2022-02-04 2023-08-10 Mereo Biopharma 5, Inc. Methods for treating cancer

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2248608B1 (OSRAM) * 1973-10-17 1977-05-27 Labo Electronique Physique
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU723939B2 (en) * 1995-06-28 2000-09-07 Imperial Cancer Research Technology Ltd Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
JPH09124697A (ja) 1995-11-01 1997-05-13 Toagosei Co Ltd ペプチド及びモノクローナル抗体
US6337387B1 (en) 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2275304T3 (es) 1997-04-04 2007-06-01 Millennium Pharmaceuticals, Inc. Nuevas composiciones de delta-3 humana y usos diagnosticos y terapeuticos para las mismas.
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US20030180784A1 (en) * 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US20060122373A1 (en) * 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
JP2001527403A (ja) 1997-04-25 2001-12-25 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6664098B1 (en) * 1997-05-14 2003-12-16 Asahi Kasei Kabushiki Kaisha Differentiation inhibitory agent
WO1998057621A1 (en) 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
CA2337492A1 (en) 1998-07-27 2000-02-10 Amgen Inc. Delta-related polypeptides
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
CA2376379C (en) 1999-06-08 2007-08-07 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
JP2004522404A (ja) 1999-12-01 2004-07-29 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
JP2003530124A (ja) 2000-04-05 2003-10-14 麒麟麦酒株式会社 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
GB0014185D0 (en) * 2000-06-09 2000-08-02 Novartis Res Found Compound and method
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20050089518A1 (en) * 2001-12-07 2005-04-28 Clarke Michael F. Prospective identification and characterization of breast cancer stem cells
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
EP1410018A1 (en) * 2001-07-25 2004-04-21 Lorantis Limited Method for detecting modultators of notch signalling
ATE462006T1 (de) 2001-08-01 2010-04-15 Univ Bristol Isoform des vegfs
EP1446424A2 (en) * 2001-11-14 2004-08-18 Lorantis Limited Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system
US20050137130A1 (en) * 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
AU2002339157A1 (en) * 2001-11-14 2003-05-26 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
GB0218879D0 (en) * 2002-08-14 2002-09-25 Lorantis Ltd Medical treatment
EP1537145A1 (en) * 2002-09-10 2005-06-08 Lorantis Limited Pharmaceutical compositions and medical treatments comprising notch ligand proteins
US7354578B2 (en) 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
JP4818917B2 (ja) 2003-08-08 2011-11-16 イミューノメディクス、インコーポレイテッド 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
FR2859725B1 (fr) 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US7354580B2 (en) 2004-06-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
AU2005265071A1 (en) 2004-06-18 2006-01-26 Memorial Sloan-Kettering Cancer Center VEGF inhibitors for the treatment of malignant pleural effusion
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US20080254031A1 (en) 2004-09-09 2008-10-16 Exonhit Therapeutics Sa Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
NZ555216A (en) 2004-11-10 2010-05-28 Hubrecht Lab Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
EP1812064A4 (en) 2004-11-19 2009-07-08 Cornell Res Foundation Inc USE OF VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 1+ CELLS IN THE TREATMENT AND MONITORING OF CANCER AND SCREENING IN CHEMOTHERAPY
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
AU2006213856B2 (en) 2005-02-11 2011-03-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
JP2008545753A (ja) 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
RU2414924C2 (ru) 2005-08-12 2011-03-27 Ридженерон Фармасьютикалз, Инк. Способы лечения заболеваний антагонистами vegf
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
EP1928486A2 (en) 2005-09-01 2008-06-11 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
NZ568739A (en) * 2005-12-16 2010-09-30 Regeneron Pharma Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists
EP1993541A2 (en) 2006-02-17 2008-11-26 Gilead Colorado, Inc. Antihypertensive therapy
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
CA2654304A1 (en) * 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
CA2654000A1 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
PL2032166T3 (pl) * 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
CN101500605B (zh) 2006-08-07 2014-04-30 瑞泽恩制药公司 Dll4拮抗剂在治疗局部缺血性损伤中的用途
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
MX2009004027A (es) 2006-10-20 2009-09-28 Schering Corp Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.
WO2008070042A2 (en) 2006-12-04 2008-06-12 Medimmune, Inc. High potency recombinant antibodies, methods for producing them and use in cancer therapy
MX2009006202A (es) 2006-12-11 2009-06-22 Genentech Inc Composiciones y metodos para el tratamiento de neoplasma.
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CN103143017A (zh) 2006-12-19 2013-06-12 基因技术公司 用于辅助和新辅助疗法以及早期肿瘤的治疗的vegf特异性拮抗剂
AU2007338734A1 (en) 2006-12-20 2008-07-03 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
MX2009011898A (es) 2007-05-04 2009-11-18 Ironwood Pharmaceuticals Inc Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009055343A2 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
WO2009053987A1 (en) 2007-10-25 2009-04-30 University Of Bristol Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf)
WO2009075565A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CA2742968C (en) 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
MY150984A (en) 2008-12-12 2014-03-31 Boehringer Ingelheim Int Anti-agf antibodies
SG175289A1 (en) 2009-04-20 2011-11-28 Genentech Inc Adjuvant cancer therapy
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011005621A1 (en) 2009-07-08 2011-01-13 Amgen Inc. Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
PL2488204T3 (pl) 2009-10-16 2016-10-31 Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych
WO2011047442A1 (en) 2009-10-23 2011-04-28 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
WO2011068840A1 (en) 2009-12-01 2011-06-09 Oncomed Pharmaceuticals, Inc. Methods for treating cancers comprising k-ras mutations
AU2011215685B2 (en) 2010-02-12 2015-08-20 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
EP3072904A1 (en) 2010-03-02 2016-09-28 Abbvie Inc. Therapeutic dll4 binding proteins
US20130323265A1 (en) 2010-11-15 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
DK3485903T5 (da) 2011-09-23 2024-09-02 Mereo Biopharma 5 Inc Vegf/dll4-bindende midler og anvendelser deraf
KR20150036603A (ko) 2012-07-13 2015-04-07 온코메드 파마슈티칼스, 인크. Rspo3 결합제 및 그의 용도
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOGUERA-TROISE I. et al. Blockade of D1l4 inhibits Tumor Growth by Promoting Non-productive Angiogenesis. Nature. December 2006, Vol 444, pages 1032-1037, *

Also Published As

Publication number Publication date
CO6180466A2 (es) 2010-07-19
US20140147443A9 (en) 2014-05-29
IL197721A (en) 2015-03-31
US20100316637A1 (en) 2010-12-16
KR101477824B1 (ko) 2015-01-02
JP2010504755A (ja) 2010-02-18
SI2066694T1 (sl) 2016-02-29
WO2008042236A3 (en) 2008-07-31
EA200970335A1 (ru) 2009-10-30
EP2066694B1 (en) 2015-11-04
JP5535633B2 (ja) 2014-07-02
JP2014158469A (ja) 2014-09-04
CY1117154T1 (el) 2017-04-05
ES2557953T3 (es) 2016-01-29
MX2009003229A (es) 2009-06-18
CA2664738A1 (en) 2008-04-10
MA30808B1 (fr) 2009-10-01
PL2066694T3 (pl) 2016-04-29
US20080187532A1 (en) 2008-08-07
AU2007305443A1 (en) 2008-04-10
US9228020B2 (en) 2016-01-05
EP3357932A1 (en) 2018-08-08
CR10667A (es) 2009-05-25
RS54452B1 (sr) 2016-06-30
NO20091635L (no) 2009-06-26
BRPI0717431A2 (pt) 2013-11-12
US9376497B2 (en) 2016-06-28
EP2562188A2 (en) 2013-02-27
EP2562188A3 (en) 2013-03-06
US20190060453A1 (en) 2019-02-28
US20160367667A1 (en) 2016-12-22
NZ576404A (en) 2012-02-24
EP2066694A4 (en) 2010-05-05
IL197721A0 (en) 2011-08-01
EA018260B1 (ru) 2013-06-28
US20130266569A1 (en) 2013-10-10
US7750124B2 (en) 2010-07-06
WO2008042236A2 (en) 2008-04-10
ZA200901615B (en) 2009-12-30
CA2664738C (en) 2017-03-07
DK2066694T3 (en) 2016-02-08
JP5997194B2 (ja) 2016-09-28
HUE028379T2 (en) 2016-12-28
PT2066694E (pt) 2016-01-27
HRP20160082T1 (hr) 2016-02-26
JP2017002076A (ja) 2017-01-05
ME02371B (me) 2016-06-20
HK1133268A1 (en) 2010-03-19
EP2066694A2 (en) 2009-06-10
KR20090078334A (ko) 2009-07-17

Similar Documents

Publication Publication Date Title
AU2007305443B2 (en) Compositions and methods for diagnosing and treating cancer
US9617340B2 (en) Compositions and methods for diagnosing and treating cancer
US8802103B2 (en) Compositions and methods for diagnosing and treating cancer
US20090208491A1 (en) Compositions and Methods for Diagnosing and Treating Cancer
CN101583624B (zh) 用于诊断和治疗癌症的组合物及其用途
HK1133268B (en) Compositions for diagnosing and treating cancer and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)